|Bid||0.00 x 1300|
|Ask||0.00 x 2900|
|Day's range||5.48 - 5.69|
|52-week range||3.28 - 26.77|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||N/A|
|Earnings date||01 Aug 2022 - 05 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.80|
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.
ANN ARBOR, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will participate in a fireside chat at the upcoming H.C. Wainwright Global Investment Conference on Tuesday, May 24th, 2022. Event:H.C. Wainwright Global Investment ConferenceDate:Tuesday, May 24th, 2022Format:Presentation and 1:1 MeetingsTime:7:00 am Eastern Standard TimeWebcast:Link A live audio webcast can be accessed on the investor and media
Esperion Therapeutics, Inc. ( NASDAQ:ESPR ) is possibly approaching a major achievement in its business, so we would...